Cerus Corporation

November 3, 2021

Forward Looking Statements

The following presentation contains forward-looking statements concerning Cerus' products, prospects and expected results, including statements relating to Cerus' revised 2021 annual product revenue guidance, including Cerus' expectations for fourth quarter product revenue; Cerus continuing to grow its business globally to gain share in the global markets for platelets; Cerus' expectation of compelling growth over the next several quarters and the potential to reach cash flow breakeven; anticipated nationwide rollout of INTERCEPT Fibrinogen Complex and the anticipated timing thereof; anticipated pipeline developments, including with respect to 7-day storage of INTERCEPT-treated platelets and the red blood cell program; expected product launches and the anticipated timing thereof; and other statements that are not historical fact. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation: risks associated with the commercialization and market acceptance of, and customer demand for, the INTERCEPT Blood System, including the risks that Cerus may not (a) meet its revised 2021 annual or fourth quarter product revenue guidance, (b) effectively launch and commercialize the INTERCEPT Blood System for Cryoprecipitation, (c) grow sales globally, including in its U.S. and European markets, and/or realize expected revenue contribution resulting from its U.S. and European market agreements, (d) realize meaningful and/or increasing revenue contributions from U.S. customers in the near term or at all, particularly since Cerus cannot guarantee the volume or timing of commercial purchases, if any, that its U.S. customers may make under Cerus' commercial agreements with these customers, (e) effectively expand its commercialization activities into additional geographies and/or (f) launch, and realize any revenue contribution from, its pipeline product candidates, whether due to Cerus' inability to obtain regulatory approval of its pipeline programs, or otherwise; risks associated with the ultimate duration and severity of the COVID-19 pandemic and resulting global economic and financial disruptions, and the current and potential future negative impacts to Cerus' business operations and financial results such as the current and potential additional disruptions to the U.S. and EMEA blood supply resulting from the evolving effects of the COVID-19 pandemic; risks associated with Cerus' lack of commercialization experience with the INTERCEPT Blood System for Cryoprecipitation and in the United States generally, and its ability to develop and maintain an effective and qualified U.S.-based commercial organization, as well as the resulting uncertainty of its ability to achieve market acceptance of and otherwise successfully commercialize the INTERCEPT Blood System in the United States, including as a result of licensure requirements that must be satisfied by U.S. customers prior to their engaging in interstate transport of blood components processed using the INTERCEPT Blood System; risks related to Fresenius Kabi's efforts to assure an uninterrupted supply of platelet additive solution (PAS); risks related to how any future PAS supply disruption could affect INTERCEPT's acceptance in the marketplace; risks related to how any future PAS supply disruption might affect current commercial contracts; risks related to Cerus' ability to demonstrate to the transfusion medicine community and other health care constituencies that pathogen reduction, including INTERCEPT Fibrinogen Complex for the treatment and control of bleeding, and the INTERCEPT Blood System is safe, effective and economical; risks related to the uncertain and time-consuming development and regulatory process, including the risks that (a) Cerus will continue to experience delays in successfully initiating, conducting or completing clinical trials as a result of the COVID-19 pandemic, (b) Cerus may be unable to comply with the FDA's post-approval requirements for the INTERCEPT Blood System, including by successfully completing required post-approval studies, which could result in a loss of U.S. marketing approval(s) for the INTERCEPT Blood System, (c) manufacturing site Biologics License Applications necessary for Cerus to distribute the INTERCEPT Blood System for Cryoprecipitation may not be obtained in a timely manner or at all, (d) Cerus may be unable to obtain CE Mark approval, or any other regulatory approvals, of the INTERCEPT red blood cell system in a timely manner or at all, (e) Cerus' PMA supplement for 7-day storage of INTERCEPT-treated platelets may not be approved in a timely manner, or at all, (f) Cerus may be unable to meet its enrollment goals for its clinical studies and the patient enrollment may otherwise be delayed or slower than expected, and (g) Cerus may otherwise be unable to obtain the requisite regulatory approvals to advance its pipeline programs and bring them to market in a timely manner or at all; risks associated with the uncertain nature of BARDA's funding over which Cerus has no control as well as actions of Congress and governmental agencies that may adversely affect the availability of funding under Cerus' BARDA agreement and/or BARDA's exercise of any potential subsequent option periods, including in connection with the general economic environment and uncertainty associated with the evolving effects of the COVID-19 pandemic, such that the anticipated activities that Cerus expects to conduct with the funds available from BARDA may be further delayed or halted and that Cerus may not otherwise realize the total potential value under its agreement with BARDA; risks related to product safety, including the risk that the septic platelet transfusions may not be avoidable with the INTERCEPT Blood System; risks related to adverse market and economic conditions, including continued or more severe adverse fluctuations in foreign exchange rates and/or continued or more severe weakening in economic conditions resulting from the evolving effects of the COVID-19 pandemic or otherwise in the markets where Cerus currently sells and is anticipated to sell its products; Cerus' reliance on third parties to market, sell, distribute and maintain its products; Cerus' ability to maintain an effective, secure manufacturing supply chain, including the risks that (a) Cerus' supply chain could be negatively impacted as a result of the evolving effects of the COVID-19 pandemic, (b) Cerus' manufacturers could be unable to comply with extensive FDA and foreign regulatory agency requirements, and (c) Cerus may be unable to maintain its primary kit manufacturing agreement and its other supply agreements with its third party suppliers; Cerus' ability to identify and obtain additional partners to manufacture the INTERCEPT Blood System for Cryoprecipitation; risks associated with Cerus' ability to access additional funds under its term loan facility and revolving line of credit and to meet its debt service obligations, and its need for additional funding; the impact of legislative or regulatory healthcare reforms that may make it more difficult and costly for Cerus to produce, market and distribute its products; risks related to future opportunities and plans, including the uncertainty of Cerus' future capital requirements and its future revenues and other financial performance and results, including with respect to its ability to reach cash flow breakeven, as well as other risks detailed in Cerus' filings with the Securities and Exchange Commission, including under the heading "Risk Factors" in Cerus' Quarterly Report on Form 10-Q, filed with the SEC on November 2, 2021, and future filings and reports by Cerus. In addition, to the extent that the COVID-19 pandemic adversely affects Cerus' business and financial results, it may also have the effect of heightening many of the other risks and uncertainties described above. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this presentation.

Focused on Safeguarding the Blood Supply

Our Mission

To make the INTERCEPT® Blood System the **standard of care** in transfusion medicine

Our Reach

Pathogen Inactivation/Reduction **Market Leader** with ~20 years in the market

Global sales in **>40 countries**

Cumulative kit sales for **>10 million INTERCEPT treated doses** of platelets & plasma

Our Technology

INTERCEPT® Blood System

- Platelets
- Plasma
- Red Blood Cells*
- Fibrinogen Complex

**In development*

Solidifying Market Leadership for Pathogen Inactivation/Reduction

Product Revenue

2017 – 2021E CAGR >30%



*2021 Product revenue guidance provided by Cerus on and as of November 2, 2021. Actual results may differ.

2021 Commercial Momentum

Full year 2021 Product Revenue Guidance
$127 million - $129 million*

Represents projected year/year growth of approximately **38% to 40%**

Standard of care in nearly one dozen countries

INTERCEPT Fibrinogen Complex **commercial launch underway**

^Standard of Care defined as more than half of the market on a unit basis

Established Moat with Products Addressing Unmet Clinical Needs

Large & Growing Addressable Market Opportunity* for INTERCEPT



>$2.3B Global Market Opportunity for Current Product Portfolio Today; >$7B with addition of Red Blood Cells

Organic market growth, expansion into untapped regions and red blood cell opportunities expected to provide **continued runway for revenue growth**

*Addressable market derived from published and estimated global blood products volumes using projected average selling prices across global markets.
‡ INTERCEPT Fibrinogen Complex is currently only marketed in the U.S. and is not licensed in EMEA
^Pathogen reduced red blood cells are in development and are not currently licensed for sale in any geography.
†2021 Product revenue guidance provided by Cerus on and as of November 2, 2021. Actual results may differ.

cerus

Current Commercial Product Portfolio

PLASMA

Proven leadership in creating a **paradigm shift** in transfusion medicine for platelets and plasma

>10 million estimated INTERCEPT treated platelet and plasma doses globally[1*]

2006

INTERCEPT Plasma CE Mark

2014

INTERCEPT Plasma FDA Approved

PLATELETS

2002

INTERCEPT Platelets CE Mark

2014

INTERCEPT Platelets FDA Approved

CRYOPRECIPITATE

Leveraging INTERCEPT to create **new products** that address critical, unmet needs

Limited launch in the U.S. in 2021; **plans for nationwide launch in 2H:22**

2020

INTERCEPT Fibrinogen Complex FDA Approved

RED CELLS



INTERCEPT Blood System for Red Blood Cells program in advanced stages of regulatory submission and Phase 3 clinical trials

[1]Dose treated estimated for Platelet and Plasma based on the number of kits sold to date
*Approximate number

cerus

Global, Growing INTERCEPT Franchise, Led by Platelet Offering

Expanding Footprint

U.S.

- INTERCEPT platelets **rapidly becoming preferred choice** of U.S. blood centers and hospitals

EMEA

- Belgium, France & Switzerland have transitioned to a **100% INTERCEPT treated platelet supply**

ROW

- Several recent accomplishments and initiatives that **continue to build INTERCEPT's global presence,** including in:



Cerus TTM* Product Revenue



*TTM = trailing twelve months

Breakthrough Device for Treating Bleeding

- The ready-to-use **INTERCEPT® Fibrinogen Complex*** is approved specifically for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency
- Immediate, enriched source of key factors in effective hemostasis[1-3]
  - Fibrinogen
  - Factor XIII
  - von Willebrand Factor
  - Other vital clotting proteins



PRODUCT	LONG-TERM STORAGE	IMMEDIATE AVAILABILITY	Massive Transfusion Protocol[4] ROUND 1	ROUND 2	ROUND 3
INTERCEPT® Fibrinogen Complex	Frozen ≤ 12 months	**Room Temp ≤ 5 Days***	✓	✓	✓
— OR —					
Cryoprecipitated AHF[5]	Frozen ≤ 12 months	**Room Temp ≤ 4-6 Hours**	*Availability delayed due to time to thaw, and establishment into later rounds of MTPs[4]* →		✓

*INTERCEPT Fibrinogen Complex is available for immediate use for up to 5 days when store liquid; and when stored frozen requires thawing prior to use.

1. Levy JH et al. Transfusion 2014;54:1389-405; quiz 8.
2. Schroeder V et al. Semin Thromb Hemost 2016;42(4):422-428.
3. Peyvandi, F. Blood Transfus 2018;16(4):326-328.
4. Holcomb JB, et al. The Journal of Trauma and Acute Care Surgery 2013;75:S31-S9.
5. AABB. Circular of Information for the Use of Human Blood and Blood Components. Bethesda, MD: AABB; 2017.

cerus

INTERCEPT Fibrinogen Complex

- First IFC revenue recognized in Q3:21

- Four Blood Center Production Partners have submitted BLA applications

- Nationwide rollout anticipated after BLAs in 2022

- Positive early customer experiences with IFC shared at SABM

INTERCEPT® Blood System Product Pipeline

Addresses Significant Global Markets & Product Improvements



[1] Phase III acute and chronic anemia studies successfully completed; CE mark submitted
[2] Patient enrollment in the RedeS and ReCePI studies is ongoing.
[3] Whole blood efforts through separate collaborations with US FDA and Swissmedic
[4] INTERCEPT Fibrinogen Complex U.S. launch underway

Strong & Improving Financial Profile

Sales Mix

>90% recurring revenue business†

Multiple opportunities for growth over the next several years

Anticipated growth across geographic segments

Product Revenue



Margins & Cash Flow

Demonstrating SG&A leverage

Mature R&D programs rolling off as launches commence

Focused on achieving cashflow breakeven as top-line growth continues

†Recurring revenue defined as kit sales for product revenues YTD @ Q3:21
*Reflects revised 2021 Product revenue guidance of $127-129 million provided by Cerus on and as of November 2, 2021. Actual results may differ.

A global leader in the critical field of **blood safety and availability.**

Proprietary and proven pathogen reduction technology is an integral part of blood safety policy in the U.S. helping to potentially **create a new standard of care** in blood safety.

An industry leader with the **only FDA-approved product for pathogen reduced platelets in the U.S.**

Financially disciplined – demonstrating operating leverage on **path to cashflow breakeven.**

Cerus Corporation

Investor Relations

IR@cerus.com

(925) 288-6137